CLAYTON, Mo., July 26, 2017 -- FutureFuel Corp. (NYSE:FF) ("FutureFuel"), a manufacturer of custom and performance chemicals and biofuels, announced today that it will release second quarter 2017 financial results after market close on Wednesday, August 9, 2017.
About FutureFuel
FutureFuel is a leading manufacturer of diversified chemical products and biofuels. FutureFuel's chemicals segment manufactures specialty chemicals for specific customers ("custom manufacturing”) as well as multi-customer specialty chemicals ("performance chemicals"). FutureFuel’s custom manufacturing product portfolio includes a laundry detergent additive, proprietary agrochemicals, adhesion promoters, a biocide intermediate, and an antioxidant precursor. FutureFuel's performance chemicals products include a portfolio of proprietary nylon and polyester polymer modifiers and several small- volume specialty chemicals and solvents for diverse applications. FutureFuel’s biofuels segment primarily produces and sells biodiesel to its customers. Please visit www.futurefuelcorporation.com for more information.
COMPANY CONTACT: FutureFuel Corp. Tom McKinlay (314) 854-8352 www.futurefuelcorporation.com


Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 



